Discovering Novel Retinal Imaging to Measure Efficacy & Select Patients with Regulatory Decision-Enabling Endpoints
June 25 - 27 | Boston, MA
The Definitive Industry Forum Dedicated to Accelerating & Implementing the Potential of Retinal Imaging
As the 2nd Retinal Imaging Biomarkers & Endpoints Summit returns to Boston this summer, join 80+ ophthalmic R&D scientists, imaging technology experts and algorithm engineers to discuss how they can harness the potential and implement novel retinal imaging tools for faster disease diagnosis and patient detection, streamlined clinical trials with accurate data readouts and non-invasive therapeutic interventions to improve patient’s quality of life.
Join 20+ expert speakers from the likes of Astellas, Boehringer Ingelheim,Genentech, Novartis and ONL Therapeutics at the only industry-dedicated event focusing on streamlining imaging data analysis with the implementation of AI-based predictive measures for earlier detection and diagnosis to optimize patient stratification, selection and recruitment for trials.
World-Class Imaging Expert Speakers Include:
Executive Director - Clinical Development
Global Head of Translational Medicine & Clinical Pharmacology, Retinal Health
Past Attendees Include:
“This Retinal Imaging Biomarkers & Endpoints meeting offers both excellent networking opportunities as well as a chance to stay on top of developments in the field.”
Principal Scientist II, Novartis